Jeremy B. Hayden, chief legal officer at Sight Sciences, Inc. (NASDAQ: SGHT), reported a sale of 13,761 shares of the company’s common stock on April 6, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares changed hands at prices between $3.43 and $3.58, producing roughly $48,851 in gross proceeds for Hayden.
Following the transaction, Hayden is recorded as directly holding 369,770 shares of Sight Sciences. That total comprises 87,274 shares of common stock and 282,496 shares that are obtainable through the vesting and settlement of restricted stock units (RSUs).
Market context for the transaction shows the stock trading at $3.50, a level that represents a 56% decline year-to-date. The share price has exhibited notable range over the last 52 weeks, moving between a low of $2.05 and a high of $9.24. InvestingPro’s analysis places the stock near a Fair Value estimate of $3.40. Investors using that platform can access eight additional InvestingPro Tips and a Pro Research Report that covers SGHT among more than 1,400 U.S. equities.
Corporate developments for Sight Sciences include quarterly results for the fourth quarter of 2025 that outperformed analyst expectations. The company reported an earnings per share of -$0.08, better than the consensus estimate of -$0.15. Revenue for the period reached $20.4 million, slightly above projected sales of $20.17 million, reflecting a 7% year-over-year increase.
On the legal front, Sight Sciences secured a favorable decision in litigation with Alcon Inc. The U.S. District Court for the District of Delaware awarded $34 million in damages for patent infringement, consisting of $5.5 million in lost profits and $28.5 million in royalty damages tied to sales of Alcon’s Hydrus Microstent.
Following these results and the legal ruling, William Blair reaffirmed its Outperform rating on Sight Sciences, citing effective expense control as a contributor to the company’s earnings performance.
Summary of the key transaction and company highlights:
- Insider sale: 13,761 shares sold at $3.43 to $3.58 on April 6, 2026, netting ~ $48,851.
- Hayden holdings after sale: 369,770 shares (87,274 common; 282,496 RSUs).
- Company performance: Q4 2025 EPS -$0.08 vs -$0.15 estimate; revenue $20.4M vs $20.17M estimate (7% increase).
- Legal award: $34M in damages from the U.S. District Court for the District of Delaware related to Alcon’s Hydrus Microstent sales.
- Market context: SGHT trading at $3.50, 52-week range $2.05 to $9.24, InvestingPro Fair Value $3.40.